A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer

BACKGROUND: The pancreatic tumor microenvironment is rich in receptors for platelet-derived growth factor (PDGFRs). Imatinib mesylate (IM) inhibits PDGFRs and decreases tumor interstitial fluid pressure, potentially improving drug access. These data and promising results in a phase 1 trial formed th...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Moss, Rebecca A., Moore, Dirk, Mulcahy, Mary F., Nahum, Kenneth, Saraiya, Biren, Eddy, Simantini, Kleber, Martin, Poplin, Elizabeth A.
格式: Artigo
語言:Inglês
出版: International Society of Gastrointestinal Oncology 2012
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3415717/
https://ncbi.nlm.nih.gov/pubmed/22888387
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍